BACKGROUND: Continuous antiretroviral therapy (ART) is important for maintaining viral suppression. This analysis estimates prevalence of and reason for ART discontinuation. METHODS: Three-stage sampling was used to obtain a nationally representative, cross-sectional sample of HIV-infected adults receiving HIV care. Face-to-face interviews and medical record abstractions were collected from June 2009 to May 2010. Data were weighted based on known probabilities of selection and adjusted for nonresponse. Patient characteristics of ART discontinuation, defined as not currently taking ART, stratified by provider-initiated versus non-provider-initiated discontinuation, were examined. Weighted logistic regression models predicted factors associated with ART discontinuation. RESULTS: Of adults receiving HIV care in the United States who reported ever initiating ART, 5.6% discontinued treatment. Half of those who discontinued treatment reported provider-initiated discontinuation. Provider-initiated ART discontinuation patients were more likely to have a nadir CD4 ≥ 200 cells per cubic millimeter. Non-provider-initiated ART discontinuation patients were more likely to have unmet need for supportive services and to have not received HIV care in the past 3 months. Among all patients who discontinued, younger age, female gender, not having continuous health insurance, incarceration, injection drug use, nadir CD4 count ≥ 2 00 cells per cubic millimeter, unmet need for supportive services, no care in the past 3 months and HIV diagnosis ≥ 5 years before interview were independently associated with ART discontinuation. CONCLUSIONS: These findings inform development of interventions to increase ART persistence by identifying groups at increased risk of ART discontinuation. Evidence-based interventions targeting vulnerable populations are needed and are increasingly important as recent HIV treatment guidelines have recommended universal ART.
BACKGROUND: Continuous antiretroviral therapy (ART) is important for maintaining viral suppression. This analysis estimates prevalence of and reason for ART discontinuation. METHODS: Three-stage sampling was used to obtain a nationally representative, cross-sectional sample of HIV-infected adults receiving HIV care. Face-to-face interviews and medical record abstractions were collected from June 2009 to May 2010. Data were weighted based on known probabilities of selection and adjusted for nonresponse. Patient characteristics of ART discontinuation, defined as not currently taking ART, stratified by provider-initiated versus non-provider-initiated discontinuation, were examined. Weighted logistic regression models predicted factors associated with ART discontinuation. RESULTS: Of adults receiving HIV care in the United States who reported ever initiating ART, 5.6% discontinued treatment. Half of those who discontinued treatment reported provider-initiated discontinuation. Provider-initiated ART discontinuation patients were more likely to have a nadir CD4 ≥ 200 cells per cubic millimeter. Non-provider-initiated ART discontinuation patients were more likely to have unmet need for supportive services and to have not received HIV care in the past 3 months. Among all patients who discontinued, younger age, female gender, not having continuous health insurance, incarceration, injection drug use, nadir CD4 count ≥ 2 00 cells per cubic millimeter, unmet need for supportive services, no care in the past 3 months and HIV diagnosis ≥ 5 years before interview were independently associated with ART discontinuation. CONCLUSIONS: These findings inform development of interventions to increase ART persistence by identifying groups at increased risk of ART discontinuation. Evidence-based interventions targeting vulnerable populations are needed and are increasingly important as recent HIV treatment guidelines have recommended universal ART.
Authors: Terry R Barclay; Charles H Hinkin; Steven A Castellon; Karen I Mason; Matthew J Reinhard; Sarah D Marion; Andrew J Levine; Ramani S Durvasula Journal: Health Psychol Date: 2007-01 Impact factor: 4.267
Authors: Patricia A Garvie; Patricia M Flynn; Marvin Belzer; Paula Britto; Chengcheng Hu; Bobbie Graham; Michael Neely; George D McSherry; Stephen A Spector; Aditya H Gaur Journal: J Adolesc Health Date: 2010-12-18 Impact factor: 5.012
Authors: M J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood Journal: J Infect Dis Date: 2011-05-01 Impact factor: 5.226
Authors: Sheri D Weiser; Edward A Frongillo; Kathleen Ragland; Robert S Hogg; Elise D Riley; David R Bangsberg Journal: J Gen Intern Med Date: 2008-10-25 Impact factor: 5.128
Authors: Yolanda Barrón; Stephen R Cole; Ruth M Greenblatt; Mardge H Cohen; Kathryn Anastos; Jack A DeHovitz; Robert Delapenha; Stephen J Gange Journal: AIDS Date: 2004-07-23 Impact factor: 4.177
Authors: Mirjam-Colette Kempf; Maria Pisu; Anastasiya Dumcheva; Andrew O Westfall; J Michael Kilby; Michael S Saag Journal: J Acquir Immune Defic Syndr Date: 2009-11-01 Impact factor: 3.731
Authors: Linda Beer; James Heffelfinger; Emma Frazier; Christine Mattson; Brad Roter; Elizabeth Barash; Susan Buskin; Todd Rime; Eduardo Valverde Journal: Open AIDS J Date: 2012-09-07
Authors: Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Anne K Monroe; Catherine R Lesko; Geetanjali Chander; Bryan Lau; Jeanne Keruly; Heidi M Crane; K Rivet Amico; Sonia Napravnik; E Byrd Quinlivan; Michael J Mugavero Journal: AIDS Care Date: 2019-02-19
Authors: Christine Oramasionwu; Stacy Cooper Bailey; Terence L Johnson; Lu Mao Journal: AIDS Res Hum Retroviruses Date: 2014-11-11 Impact factor: 2.205
Authors: Christy E Newman; Limin Mao; Asha Persson; Martin Holt; Sean Slavin; Michael R Kidd; Jeffrey J Post; Edwina Wright; John de Wit Journal: AIDS Patient Care STDS Date: 2015-03-25 Impact factor: 5.078
Authors: Inge B Corless; Alex J Hoyt; Lynda Tyer-Viola; Elizabeth Sefcik; Jeanne Kemppainen; William L Holzemer; Lucille Sanzero Eller; Kathleen Nokes; J Craig Phillips; Carol Dawson-Rose; Marta Rivero-Mendez; Scholastika Iipinge; Puangtip Chaiphibalsarisdi; Carmen J Portillo; Wei-Ti Chen; Allison R Webel; John Brion; Mallory O Johnson; Joachim Voss; Mary Jane Hamilton; Kathleen M Sullivan; Kenn M Kirksey; Patrice K Nicholas Journal: AIDS Patient Care STDS Date: 2017-05 Impact factor: 5.078
Authors: Chad J Achenbach; Ashley L Buchanan; Stephen R Cole; Lifang Hou; Michael J Mugavero; Heidi M Crane; Richard D Moore; Richard H Haubrich; Satish Gopal; Joseph J Eron; Peter W Hunt; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata Journal: Clin Infect Dis Date: 2014-02-12 Impact factor: 9.079
Authors: Ellen F Eaton; Ashutosh Tamhane; Thibaut Davy-Mendez; William C Mathews; Richard D Moore; Michael S Saag; Michael J Mugavero Journal: AIDS Date: 2018-01-28 Impact factor: 4.177
Authors: Andrew Edmonds; Christina Ludema; Joseph J Eron; Stephen R Cole; Adebola A Adedimeji; Mardge H Cohen; Hannah L Cooper; Margaret Fischl; Mallory O Johnson; Denise D Krause; Dan Merenstein; Joel Milam; Tracey E Wilson; Adaora A Adimora Journal: J Womens Health (Larchmt) Date: 2017-07-06 Impact factor: 2.681